Answers are grounded in this paper and cite their sources.
and high-throughput screening approach followed by medicinal optimization to identify first-in-class, oral and safe antagonists of ALDH1A3 with potent anti-tumor immunotherapeutic activity and an optimized drug development profile.
No takes yet. Share an insight, caveat, or question.
Esposito et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: